Creation of a S1P Lyase bacterial surrogate for structure-based drug design.
Argiriadi, M.A., Banach, D., Radziejewska, E., Marchie, S., DiMauro, J., Dinges, J., Dominguez, E., Hutchins, C., Judge, R.A., Queeney, K., Wallace, G., Harris, C.M.(2016) Bioorg Med Chem Lett 26: 2293-2296
- PubMed: 27013389 
- DOI: 10.1016/j.bmcl.2016.02.084
- Primary Citation of Related Structures:  
5EUD, 5EUE - PubMed Abstract: 
S1P Lyase (SPL) has been described as a drug target in the treatment of autoimmune diseases. It plays an important role in maintaining intracellular levels of S1P thereby affecting T cell egress from lymphoid tissues. Several groups have already published approaches to inhibit S1P Lyase with small molecules, which in turn increase endogenous S1P concentrations resulting in immunosuppression ...